<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04396340</url>
  </required_header>
  <id_info>
    <org_study_id>XMT-1592-1</org_study_id>
    <nct_id>NCT04396340</nct_id>
  </id_info>
  <brief_title>First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b</brief_title>
  <official_title>A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mersana Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IQVIA Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mersana Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to&#xD;
      evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1b trial is an open-label, multi-center study of XMT-1592 administered as an&#xD;
      intravenous infusion once every 3 weeks. The dose-escalation (DES) segment of the study will&#xD;
      establish the expansion (EXP) dose and is intended to establish the maximum tolerated dose&#xD;
      (MTD) or recommended Phase 2 dose (RP2D) for XMT-1592 in patients with high grade serous&#xD;
      ovarian cancer (HGSOC) or non-small cell lung cancer (NSCLC), adenocarcinoma subtype. The EXP&#xD;
      segment of the study will consist of 2 parallel cohorts of patients (HGSOC and NSCLC) to&#xD;
      confirm the MTD or RP2D and estimate the objective response rate in each selected patient&#xD;
      population. In DES, the observation period for dose-limiting toxicities is 21 days, between&#xD;
      Day 1 through the end of Cycle 1 which includes the pre-dose assessments before receiving the&#xD;
      Cycle 2 dose. All adverse events (AEs) will be graded according to NCI, CTCAE v5.0). In&#xD;
      general, AEs ≥Grade 3 are dose-limiting toxicities with some modifications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, dose escalation to reach MTD. The MTD will be confirmed in 2 parallel cohorts: (1) patients with platinum-resistant ovarian cancer; (2) patients with non-squamous NSCLC, adenocarcinoma subtype.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose or recommended Phase 2 dose</measure>
    <time_frame>Up to 36 weeks, from the date of first dose until unacceptable side effects or a dose-limiting toxicity is me</time_frame>
    <description>Evaluate adverse events and use of concomitant medication use after XMT-1592 doses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration of XMT-1592</measure>
    <time_frame>Daily for one week after first dose; weekly until 21 days after first dose; immediately before and after and 1 week after all subsequent doses</time_frame>
    <description>Determine the pharmacokinetics of XMT-1592</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of XMT-1592</measure>
    <time_frame>Daily for one week after first dose; weekly until 21 days after first dose; immediately before and after and 1 week after all subsequent doses</time_frame>
    <description>Determine the pharmacokinetics of XMT-1592</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration curve of the last measurable concentration of XMT-1592</measure>
    <time_frame>Daily for one week after first dose; weekly until 21 days after first dose; immediately before and after and 1 week after all subsequent doses</time_frame>
    <description>Determine the pharmacokinetics of XMT-1592</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antineoplastic effects of XMT-1592</measure>
    <time_frame>Every 6 weeks for up to 36 weeks</time_frame>
    <description>Monitor tumor size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody and neutralizing antibody</measure>
    <time_frame>Every 3 weeks for 9 weeks then every 6 weeks for upto 36 weeks</time_frame>
    <description>Analyze blood for antibodies to XMT-1536 and neutralizing antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Nonsmall Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XMT-1592 is administered in groups of patients who will receive doses that increase over time until the maximum tolerated dose is achieved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Confirmation of Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New groups of patients will receive XMT-1592 at the maximum tolerated dose to confirm the recommended Phase 2 dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XMT-1592</intervention_name>
    <description>XMT-1592 will be administered once every 21 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.</description>
    <arm_group_label>Confirmation of Dose</arm_group_label>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to give informed consent.&#xD;
&#xD;
          -  ECOG performance status 0 or 1.&#xD;
&#xD;
          -  Measurable disease as per RECIST, version 1.1. Resolution of all acute toxic effects&#xD;
             of prior therapy or surgical procedures to Grade ≤1 (except alopecia).&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
          -  Confirmed availability of tumor tissue blocks or freshly cut tissue slides for NaPi2b&#xD;
             testing. -In EXP, ability to undergo a fresh biopsy before enrollment, unless not&#xD;
             medically feasible.&#xD;
&#xD;
          -  For women of childbearing potential and men with partners of childbearing potential,&#xD;
             agreement to use a highly effective form of hormonal contraception or two effective&#xD;
             forms of non-hormonal contraception by the patient and/or partner, and to continue the&#xD;
             use of contraception for the duration of study treatment and for at least 6 months&#xD;
             after the last dose of study treatment.&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumors of the types specified below,&#xD;
             with incurable, locally advanced or metastatic disease that has failed standard&#xD;
             therapy or for which no standard treatment option exists.&#xD;
&#xD;
          -  Ovarian Cancer: Histological diagnosis of epithelial ovarian, fallopian tube, or&#xD;
             primary peritoneal cancer, excluding the mucinous subtype.&#xD;
&#xD;
        NSCLC: Histological diagnosis of nonsquamous NSCLC.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery within 28 days of starting study treatment; -or- systemic anti-cancer&#xD;
             therapy within the lesser of 28 days or 5 half-lives of the prior therapy before&#xD;
             starting study treatment -or- recent radiation therapy with unresolved toxicity.&#xD;
&#xD;
          -  Brain metastases that are: untreated, progressive, have required any type of major&#xD;
             treatment, e.g., whole-brain radiation treatment, adjuvant chemotherapy, gamma knife,&#xD;
             to control symptoms from brain metastases within 30 days of the first study treatment.&#xD;
             Or any history of leptomeningeal metastasis.&#xD;
&#xD;
          -  Current known active infection with HIV, hepatitis B virus, or hepatitis C virus.&#xD;
&#xD;
          -  No prior history of liver disease such as liver cirrhosis, hepatic fibrosis&#xD;
&#xD;
          -  Current severe, uncontrolled systemic disease (e.g., clinically significant&#xD;
             cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could&#xD;
             interfere with per-protocol evaluations.&#xD;
&#xD;
          -  Severe dyspnea at rest due to complications of advanced malignancy, or requiring&#xD;
             supplementary oxygen therapy.&#xD;
&#xD;
          -  Currently active pneumonitis or interstitial lung disease.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  History of other malignancy within the last 5 years, except for appropriately treated&#xD;
             carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with&#xD;
             a similar expected curative outcome.&#xD;
&#xD;
          -  Participation in the DES component of the study.&#xD;
&#xD;
          -  Prior use of mirvetuximab soravtansine or another ADC containing an auristatin or&#xD;
             maytansinoid payload.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arvin Yang, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Mersana Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leigh Keating, MS, RD</last_name>
    <phone>617-498-0020</phone>
    <email>lkeating@mersana.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henry Ford Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LaToya Allen</last_name>
      <phone>313-916-9826</phone>
    </contact>
    <investigator>
      <last_name>Ding Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49545</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Estkowski</last_name>
      <phone>616-954-5551</phone>
    </contact>
    <investigator>
      <last_name>Nehal Lakhani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>phase1@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Burns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute (SCRI)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Nurse</last_name>
      <phone>615-339-4214</phone>
    </contact>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Eamma</last_name>
      <phone>214-658-1962</phone>
    </contact>
    <investigator>
      <last_name>Minal Barve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics (START)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauryn Tuckett</last_name>
      <phone>210-593-5242</phone>
    </contact>
    <investigator>
      <last_name>Kyri Papadopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia De Leon</last_name>
      <phone>210-580-9521</phone>
    </contact>
    <investigator>
      <last_name>Anthony Tolcher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

